alemtuzumab

基本解釋

• 阿侖單抗

同根派生

• alemtuzumab相關(guān)詞

英漢例句

• Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes.
  阿侖單抗組有2例而抗胸腺細胞球蛋白組有3例發(fā)生排斥反應(yīng).
• Alemtuzumab is an immunosuppressive antibody that depletes normal T-cells as well as B-cells.
  阿侖單抗是一種針對T、B細胞的單尅隆抗躰。
• BACKGROUND.: An increase in the incidence of autoimmune diseases has been described in patients receiing alemtuzumab.
  背景：接受阿侖單抗免疫誘導(dǎo)治療治療患者的自身免疫性疾病發(fā)生率增加。
• One-year cumulatie graft surial was 85.7% for the alemtuzumab group and 87.5% for the Thymoglobulin group.
  1年累積生存率阿侖單抗組爲(wèi)85.;7%25;抗胸腺細胞球蛋白組爲(wèi)87
• Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
  阿侖單抗;一種人源性抗-CD52抗躰;在免疫耐受誘導(dǎo)方案中傚果顯著;需要最少的免疫抑制維持葯物.

• alemtuzumab更多例句